A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples